ClinicalTrials.gg
Sign In
TerminatedNCT04190628Updated May 21, 2024

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of ABM-1310 and Cobimetinib in Advanced Solid Tumor and BRAF V600 Mutation, sponsored by ABM Therapeutics Corporation. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-21.

Sponsored by ABM Therapeutics Corporation · Phase 1, Interventional, and Treatment

Why this study was terminated
Not related to safety concerns or lack of efficacy

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 6 months ago, and no results have been posted to the registry.
Phase
Phase 1
Study type
Interventional
Enrollment
53
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally advanced or metastatic solid tumors who have no effective standard treatment options available, as monotherapy in patients with documented BRAF V600 mutation, or in combination with cobimetinib (Cotellic®) in adult patients who have documented BRAF mutation and progressive disease or intolerance to at least one prior line of systemic therapy.

Read the detailed description

This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally advanced or metastatic solid tumors who have no effective standard treatment options available, as monotherapy in patients with documented BRAF V600 mutation, or in combination with cobimetinib (Cotellic®) in adult patients who have documented BRAF mutation and progressive disease or intolerance to at least one prior line of systemic therapy. The primary objectives of this study are to determine the Maximum Tolerated Dose (MTD) and/or the Recommended Phase II Dose (RP2D) of both single agent and combination treatment and to assess the safety and tolerability of ABM-1310 as a monotherapy and in combination.

Study consists of three Parts:

Part A: The starting dose of ABM-1310 is 25 mg po bid, and dose escalation will be guided by a "3+3" design. ABM-1310 will be administered twice daily on a continuous schedule. Each treatment cycle consists of 28 days.

Part B: The starting dose of ABM-1310 will be a dose below the MTD that has been demonstrated to be safe in Part A Monotherapy. A classic "3+3" design will guide the dose escalation. At each dose level, ABM-1310 will be administered in combination with 60 mg cobimetinib (Cotellic ®) once daily (qd) for the first 21 days of each 28-day treatment cycle.

Part C:

  • In C-1 (Monotherapy - Primary CNS Tumors) and C-2 (Monotherapy - Advanced or Metastatic solid tumors excluding Primary CNS tumors with or without Brain Metastasis), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.
  • In C-3 (Combination therapy - Advanced/Metastatic Solid Tumors including Primary CNS Tumors but excluding Melanoma with Brain Metastsis) and C-4 (Combination therapy - Melanoma with Brain Metastasis), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B, in combination with cobimetinib (Cotellic®) 60 mg administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.

Dose limiting toxicity (DLT) will be evaluated and managed per the pre-defined DLT criteria and rules specified in the protocol. MTD and/or RP2D will be confirmed in a dose confirmation cohort.

02

Conditions studied

  • Advanced Solid Tumor
  • BRAF V600 Mutation

Keywords

  • Melanoma
  • Colorectal Cancer
  • Glioblastoma
  • Cholangiocarcinoma
  • Non-small Cell Lung Cancer
  • Thyroid Cancer
  • Ovarian Cancer
03

In context

Melanoma

3,073 studies on the registry are indexed under Melanoma; 529 are open to participants now.

This study's enrollment of 53 is above the median of 38 across 2,400 interventional studies indexed under Melanoma.

Browse Melanoma studies →

Lead sponsor

ABM Therapeutics Corporation is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects age 18 years and older who are able to sign informed consent and to comply with the protocol

  2. Patients with histologically or cytologically-documented, locally advanced, or metastatic solid tumor malignancy that has either (a) progressed on at least one line of prior standard systemic therapy, (b) for which no standard therapy exists, or (c) standard therapy is not considered appropriate by the patient or treating physician. There is no limit to the number of prior treatment regimens

    • Part A: Patients with advanced or metastatic solid tumors with documentation of positive BRAF V600E mutation, or any other BRAF V600 mutation is required for enrollment
    • Part B: Patients with advanced or metastatic solid tumors with documentation of any BRAF mutation.

    • Part C:

      1. C-1: Patients with primary central nervous system (CNS) tumors and documentation of positive BRAF V600 mutation
      2. C-2: Patients with advanced or metastatic solid tumors and documentation of positive BRAF V600 mutation excluding primary CNS tumor
      3. C-3: Patients with advanced or metastatic solid tumors and documentation of positive BRAF mutation including primary CNS tumors but excluding melanoma with brain metastasis
      4. C-4: Patients with melanoma with brain metastasis and documentation of positive BRAF mutation

    Patients with active or stable brain metastasis that are asymptomatic, or that are symptomatic treated with a total daily dose of no more than 4 mg of dexamethasone (or equivalent) that is stable or tapering for at least 2 weeks prior to first treatment are eligible for enrollment. Patients with neurologic signs and symptoms who are not being treated with steroids are eligible and should have no experience of seizure within 2 weeks prior to first treatment.

  3. Must have at least one measurable lesion as defined by RECIST V1.1 criteria for solid tumors or the RANO criteria for primary CNS tumors, such as gliomas.

    • For solid tumor with Brain Metastases:
    • Measurable brain lesions that are 0.5 - 3 cm in longest diameter as defined by the modified RECIST V1.1 criteria are allowed.
    • Brain lesion size > 3 cm is not eligible.
  4. ECOG performance status of 0 or 1 or Karnofsky performance status of ≥ 70

  5. Adequate organ function confirmed at screening and within 28 days of initiating treatment, as evidenced by:

    • Absolute Neutrophil Count (ANC) ≥ 1.0 x 10\^9/L
    • Hemoglobin (Hgb) ≥ 9 g/dl
    • Platelets (Plt) ≥ 100 x 10\^9/L
    • AST/ALT ≤ 2.5 x Upper Limit of Normal (ULN) or ≤ 5.0 x ULN if liver metastases are present
    • Total bilirubin ≤ 1.5 x ULN, or direct bilirubin \<ULN for patients with total bilirubin levels >1.5 ULN
    • Serum creatinine \<1.5 x ULN or measured or calculated (per institutional standard) creatinine clearance of > 60 mL/min.
  6. Negative pregnancy test within 72 hours before starting study treatment in all pre-menopausal women and women \<12 months after the onset of menopause
  7. Male and female subjects must agree to take sufficient contraceptive methods to avoid pregnancy before first dose of study treatment, during the study, and for at least 3 months after ceasing study treatment

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant or breast-feeding
  2. Women of child-bearing potential (WOCBP) who does not use adequate birth control
  3. Patients with any hematologic malignancy. This includes leukemia, lymphoma, and multiple myeloma
  4. Have a second primary malignancy that, in the judgment of the investigator, may affect the interpretation of results
  5. Patients with carcinomatous meningitis (leptomeningeal disease (LMD))
  6. Patients with history of stroke ≤ 6 months prior to starting study drug
  7. Patients who have had an experience of seizure within 14 days prior to first treatment

  8. Impaired cardiac function or clinically significant cardiac diseases, including but not limited to any of the following:

    • Left Ventricular Ejection Fraction (LVEF) \< 45% as determined by MUGA scan or ECHO
    • Congenital long QT syndrome
    • QTcF ≥ 450 msec (mean) on screening (Triplicate 12-Lead ECG)
    • Unstable angina pectoris ≤ 6 months prior to starting study drug
    • Acute myocardial infarction ≤ 6 months prior to starting study drug
    • Use of pacemaker

  9. Patients with

    • Unresolved diarrhea ≥ CTCAE Grade 2, or
    • Impairment of gastrointestinal (GI) function, or
    • GI disease or conditions that may significantly alter the absorption of ABM-1310 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
  10. Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., uncontrolled hypertriglyceridemia [triglycerides >500 mg/dL], active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol
  11. Extensive prior radiotherapy to more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation within 5 years

  12. Patients who have received chemotherapy, targeted therapy or immunotherapy ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy, except:

    • ≤ 6 weeks for nitrosourea or mitomycin-C
    • ≤ 5 half-lives or 2 weeks for small molecule inhibitor treatment, whichever is longer
  13. Patients who have received wide field radiotherapy ≤ 4 weeks, limited field radiation for palliation ≤ 2 weeks, prior whole-brain radiotherapy (WBRT) ≤ 4 weeks or stereotactic radiosurgery (SRS) ≤ 2 weeks (one week for patients with primary CNS tumor such as GBM or with brain metastasis) prior to starting study drug or patients who have not recovered from side effects of such therapy
  14. Patients who have undergone major surgery ≤ 4 weeks in general prior to starting study drug or who have not recovered from side effects of such therapy. However, a minimum of 2 weeks recovery time from major surgery prior to starting study drug is acceptable if in investigator's opinion the patient has recovered from surgery.
  15. Patients who are currently receiving treatment with therapeutic doses of warfarin sodium or any other coumarin-derivative anticoagulants
  16. Patients who have received systemic corticosteroids ≤ 2 weeks prior to starting study drug or who have not recovered from the side effects of such treatment. Therapeutic doses of corticosteroids up to 4 mg/day of dexamethasone, or equivalent are allowed. Note: Patients that are taking replacement doses of steroids are eligible
  17. Patients who are currently receiving treatment with medication that has known risk to prolong the QT interval, and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug
  18. Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory; patients with well controlled HIV might be enrolled per investigator's discretion)
  19. Known history of active infection with Hepatitis B (e.g., HBsAg reactive), or Hepatitis C (e.g., S RNA (qualitative) is detected)
  20. History of alcohol or drug abuse ≤ 3 months prior to first dose
  21. Has a history or current evidence of any condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might confound the results of the trial, interfere with the patient's participation and compliance in the trial
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Monotherapy Dose Escalation

    A classic "3+3" design will be used to determine MTD and RP2D. Three to six patients per treatment cohort will be assigned to receive sequentially higher oral doses of ABM-1310 on a twice daily schedule (bid) for 28-day cycles, starting at a dose of 25 mg bid. Patients will receive twice daily oral doses of ABM-1310 continuously until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.

    Drug: ABM-1310

  • Experimental
    Combination Therapy Dose Escalation

    A classic "3+3" design will guide the dose escalation in Part B. At each dose level, ABM-1310 will be administered in combination with cobimetinib (Cotellic ®) once daily (qd) for the first 21 days of each 28-day treatment cycle. The starting dose of ABM-1310 will be a dose below the MTD that has been demonstrated to be safe in Part A Monotherapy.

    Drug: ABM-1310 · Drug: Cobimetinib

  • Experimental
    Monotherapy Therapy Dose Expansion-1

    \- In C-1(Monotherapy - Primary CNS Tumors), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.

    Drug: ABM-1310

  • Experimental
    Monotherapy Therapy Dose Expansion-2

    \- In C-2 (Monotherapy - Advanced or Metastatic Solid Tumors excluding Primary CNS Tumor with or without Brain Metastasis), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.

    Drug: ABM-1310

  • Experimental
    Combination Therapy Dose Expansion-1

    \- In C-3 (Combination therapy - Advanced/Metastatic Solid Tumors including Primary CNS tumors but excluding Melanoma with Brain metastasis), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B, in combination with cobimetinib (Cotellic®) 60 mg administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.

    Drug: ABM-1310 · Drug: Cobimetinib

  • Experimental
    Combination Therapy Dose Expansion-2

    \- In C-4 (Combination therapy - Melanoma with Brain Metastasis), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B, in combination with cobimetinib (Cotellic®) 60 mg administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.

    Drug: ABM-1310 · Drug: Cobimetinib

Interventions

  • DrugABM-1310

    Part A: Starting dose at 25 mg by mouth twice daily. Part B: Starting dose at a dose below the MTD( Maximum Tolerated Dose) that has been demonstrated to be safe in Part A. Part C-1 and C-2: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met. Part C-3 and C-4: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.

    Also known as: ABM1310

  • DrugCobimetinib

    Part B: orally administered once daily. Part C-3 and C-4: Continuous once daily oral dose from Part B, administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met. Dose formulation is 60 mg capsules.

    Also known as: Cotellic®

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)

    Determine Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) as a monotherapy and in combination therapy in Part A and Part B

    Time frame: End of Cycle 1 (each cycle is 28 days) or up to treatment discontinuation (an average of 6 months)

  2. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Safety and tolerability of ABM-1310 as a monotherapy and in combination therapy at Part A and Part B's Recommended Phase 2 dose (RP2D) in Part C

    Time frame: Up to study discontinuation (an average of 1 year)

  3. Number of participants with abnormal laboratory values

    Safety and tolerability of ABM-1310 as a monotherapy and in combination therapy at Part A and Part B's Recommended Phase 2 Dose (RP2D) in Part C

    Time frame: Up to study discontinuation (an average of 1 year)

Secondary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Safety and tolerability of ABM-1310 as a single agent and in combination therapy in Part A and Part B

    Time frame: Up to 30 days from treatment discontinuation

  2. Number of participants with abnormal laboratory values

    Safety and tolerability of ABM-1310 as a single agent and in combination therapy in Part A and Part B

    Time frame: Up to 30 days from treatment discontinuation

  3. Area under the concentration time curve (AUC)

    Pharmacokinetic (PK) profile of ABM-1310 as a single agent and in combination therapy

    Time frame: Up to Day 1 of Cycle 2 (each cycle is 28 days)

  4. Maximum plasma concentration (Cmax)

    Pharmacokinetic (PK) profile of ABM-1310 as a single agent and in combination therapy

    Time frame: Up to Day 1 of Cycle 2 (each cycle is 28 days)

  5. Steady-state concentration (Css)

    Pharmacokinetic (PK) profile of ABM-1310 as a single agent and in combination therapy

    Time frame: Up to Day 1 of Cycle 2 (each cycle is 28 days)

  6. Time to maximum plasma concentration (Tmax)

    Pharmacokinetic (PK) profile of ABM-1310 as a single agent and in combination therapy

    Time frame: Up to Day 1 of Cycle 2 (each cycle is 28 days)

  7. Half-life (T1/2)

    Pharmacokinetic (PK) profile of ABM-1310 as a single agent and in combination therapy

    Time frame: Up to Day 1 of Cycle 2 (each cycle is 28 days)

  8. Objective Response Rate (ORR)

    Preliminary efficacy of ABM-1310 as a single agent and in combination therapy

    Time frame: Up to study discontinuation (an average of 1 year)

  9. Disease Control Rate (DCR)

    Preliminary efficacy of ABM-1310 as a single agent and in combination therapy

    Time frame: Up to study discontinuation (an average of 1 year)

  10. Duration of Response (DOR)

    Preliminary efficacy of ABM-1310 as a single agent and in combination therapy

    Time frame: Up to study discontinuation (an average of 1 year)

  11. Progression free survival (PFS)

    Preliminary efficacy of ABM-1310 as a single agent and in combination therapy

    Time frame: Up to study discontinuation (an average of 1 year)

  12. Overall Survival (OS)

    Preliminary efficacy of ABM-1310 as a single agent and in combination therapy

    Time frame: Up to study discontinuation (an average of 1 year)

  13. Time to Response (TTR)

    Preliminary efficacy of ABM-1310 as a single agent and in combination therapy

    Time frame: Up to study discontinuation (an average of 1 year)

Other outcomes

  1. Exploratory preliminary efficacy in patients by types of BRAF V600 mutation

    Preliminary efficacy of ABM-1310 as a single agent and in combination therapy

    Time frame: Up to study discontinuation (an average of 1 year)

  2. Identification of major metabolite of ABM-1310 in patients who receive ABM-1310 monotherapy in Part C

    Tests to identify major metabolite of ABM-1310 by a central lab on the post-dose blood samples from patients who receive ABM-1310 monotherapy in Part C

    Time frame: Up to study discontinuation (an average of 1 year)

07

Study locations

8 sites
  • University of California- San Francisco
    San Francisco, California 94158, United States
  • Stanford University School of Medicine
    Stanford, California 94305, United States
  • University of Miami Hospital Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Robert H. Lurie Comprehensive Cancer Center (Northwestern University)
    Chicago, Illinois 60611, United States
  • Henry Ford Cancer Institute
    Detroit, Michigan 48202, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • UTHealth Science Center Houston Department of Neurosurgery
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Apr 2024, 45 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2019
First posted
Dec 9, 2019
StartActual
Jun 16, 2020
Primary completionActual
Apr 5, 2024
CompletionActual
Apr 5, 2024
Last update
May 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04190628
Lead sponsor
ABM Therapeutics Corporation
Responsible party
Sponsor
First posted
Dec 9, 2019
Start date
Jun 16, 2020
Primary completion
Apr 5, 2024
Completion
Apr 5, 2024
Last update
May 21, 2024

Study contacts

Sarina A Piha-Paul, M.D.
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Melanoma →

Other studies from this sponsor

ABM Therapeutics Corporation

Start the discussion